Research Reports

Key takeaways

Operating income was -$11.9M, reflecting significant expansion of corporate activity and headcount in connection with becoming a public company and completing the Merger.

Net income was -$6.0M, partially offset by gains from digital assets.

EPS was -$0.55.

Free cash flow was -$9.0M, driven by operating cash burn of $8.9M and capital expenditures of $57K.

Management believes remaining PIPE tranches and NILA token sales are primary capital sources to fund operations over the next twelve months.

Full analysis

IPO and Merger Drove Operating Loss

Digital Asset Gains Offset Operating Loss

Net income was -$6.0 million, reflecting that gains from digital assets partially offset the operating loss. The company holds NILA Tokens, which are classified within Level 2 as they trade on a limited number of centralized exchanges with modest daily trading volume.

Cash Burn and Financing

Balance Sheet Transformation and Liquidity Risk

Going Concern and Outlook

Management believes that the remaining available tranches under the Securities Purchase Agreement, combined with continued NILA Token sales for USDT proceeds and potential additional equity or debt financing, represent the primary sources of capital to fund operations over the next twelve months. Our ability to continue as a going concern depends on our ability to raise additional capital and execute our operational plans.

APUS · Apimeds Pharmaceuticals US, Inc